Prognostic significance of circulating immune-inflammatory biomarkers IL-6 and systemic immune-inflammation index in hepatocellular carcinoma treated with immune checkpoint inhibitors: A meta-analysis.

IF 1.9 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2026-06-16 DOI:10.5937/jomb0-64710

Enze Hu, Yuanfu Qiu

{"title":"Prognostic significance of circulating immune-inflammatory biomarkers IL-6 and systemic immune-inflammation index in hepatocellular carcinoma treated with immune checkpoint inhibitors: A meta-analysis.","authors":"Enze Hu, Yuanfu Qiu","doi":"10.5937/jomb0-64710","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is characterized by a chronic inflammatory and immunologically dysregulated microenvironment. Circulating immune-inflammatory biomarkers reflect systemic biochemical and immune alterations and may provide laboratory-accessible indicators for prognosis assessment. However, the prognostic value of interleukin-6 (IL-6) and the systemic immune-inflammation index (SII) in HCC patients receiving immune checkpoint inhibitors (ICIs) remains incompletely defined.Methods: A comprehensive literature search was conducted across PubMed, Embase, Web of Science, the Cochrane Library, CNKI, and Wanfang Data to identify cohort studies evaluating circulating IL-6 and/or SII in HCC patients treated with ICIs. Hazard ratios (HR) with 95% confidence intervals (CI) for progression-free survival (PFS) and overall survival (OS) were pooled using fixedor random-effects models. Subgroup and sensitivity analyses were performed to explore sources of heterogeneity.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"45 6","pages":"1222-1231"},"PeriodicalIF":1.9000,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13600549/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-64710","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) is characterized by a chronic inflammatory and immunologically dysregulated microenvironment. Circulating immune-inflammatory biomarkers reflect systemic biochemical and immune alterations and may provide laboratory-accessible indicators for prognosis assessment. However, the prognostic value of interleukin-6 (IL-6) and the systemic immune-inflammation index (SII) in HCC patients receiving immune checkpoint inhibitors (ICIs) remains incompletely defined.

Methods: A comprehensive literature search was conducted across PubMed, Embase, Web of Science, the Cochrane Library, CNKI, and Wanfang Data to identify cohort studies evaluating circulating IL-6 and/or SII in HCC patients treated with ICIs. Hazard ratios (HR) with 95% confidence intervals (CI) for progression-free survival (PFS) and overall survival (OS) were pooled using fixedor random-effects models. Subgroup and sensitivity analyses were performed to explore sources of heterogeneity.

查看原文本刊更多论文

循环免疫炎症生物标志物IL-6和全身免疫炎症指数在免疫检查点抑制剂治疗的肝细胞癌中的预后意义：一项荟萃分析

背景：肝细胞癌（HCC）以慢性炎症和免疫微环境失调为特征。循环免疫炎症生物标志物反映了系统生化和免疫改变，可能为预后评估提供实验室可获得的指标。然而，在接受免疫检查点抑制剂（ICIs）治疗的HCC患者中，白细胞介素-6 （IL-6）和全身免疫炎症指数（SII）的预后价值仍未完全确定。方法：通过PubMed、Embase、Web of Science、Cochrane图书馆、中国知网和万方数据进行全面的文献检索，以确定评估ICIs治疗的HCC患者循环IL-6和/或SII的队列研究。使用固定或随机效应模型对无进展生存期（PFS）和总生存期（OS）的风险比（HR）和95%置信区间（CI）进行汇总。进行亚组分析和敏感性分析以探索异质性的来源。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.